Successful Treatment of Crizotinib-Associated Severe Hepatotoxicity in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Soonchunhyang Medical Science
; : 35-38, 2014.
Article
em En
| WPRIM
| ID: wpr-107299
Biblioteca responsável:
WPRO
ABSTRACT
Crizotinib-associated severe hepatotoxicity has been rarely reported and experts recommended stopping crizotinib treatment in patients with grade 3/4 transaminase elevation. We experienced a case of anaplastic lymphoma kinase-positive non-small cell lung cancer occurring as a result of severe hepatotoxicity due to crizotinib-associated hepatitis, accompanied by the reactivation of chronic hepatitis B, which was reversed with dose reduction and anti-viral therapy. Our case highlights the possibility that crizotinib might induce hepatitis and this might be associated with the underlying presence of chronic hepatitis B. In addition, crizotinib could be continued with reduced unless there are any other therapeutic options.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Hepatite B Crônica
/
Hepatite
/
Linfoma
Limite:
Humans
Idioma:
En
Revista:
Soonchunhyang Medical Science
Ano de publicação:
2014
Tipo de documento:
Article